Edwards Lifesciences (EW) announced 10-year results from the Commence aortic trial, reinforcing the long-term durability and sustained performance of its proprietary Resilia tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. At 10 years, Commence trial data showed that patients treated with Edwards’ surgical valves featuring Resilia tissue experienced: 97.9% freedom from structural valve deterioration, SVD; 97.8% freedom from reoperation due to SVD; 98.6% freedom from non-structural valve dysfunction; Sustained hemodynamic performance, including stable gradients and effective orifice area over time
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $110 from $104 at Barclays
- Edwards Lifesciences price target raised to $90 from $89 at Truist
- Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
- Edwards Lifesciences price target raised to $100 from $98 at BTIG
- Edwards Lifesciences price target lowered to $85 from $87 at Canaccord